Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Aldeyra Therapeu
(NQ:
ALDX
)
10.52
USD
+0.08 (+0.77%)
Streaming Delayed Price
Updated: 9:43 AM EDT, Apr 23, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Aldeyra Therapeu
< Previous
1
2
3
4
5
6
7
8
Next >
Aldeyra Therapeutics Releases Expanded Results from Allergen Chamber Trial and Announces Plans to Initiate the Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis
October 31, 2019
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated...
From
Business Wire News Releases
Aldeyra Therapeutics to Host Conference Call and Webcast to Release Expanded Results from Allergen Chamber Trial and Announce Design of Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctiviti
October 30, 2019
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, October 31, 2019 to release expanded results from its allergen chamber clinical...
From
Business Wire News Releases
ZAGENO Appoints Josef H. von Rickenbach as Chairman of its Board of Directors
October 16, 2019
From
GlobeNewswire News Releases
Aldeyra Therapeutics to Present at Ophthalmology Innovation Summit at American Academy of Ophthalmology 2019 Annual Meeting
October 07, 2019
Aldeyra Therapeutics will discuss its Phase 3 ocular programs on Thursday, October 10 at the Ophthalmology Innovation Summit in San Francisco.
From
Business Wire News Releases
Aldeyra Therapeutics to Present Phase 3 ALLEVIATE Trial Results in Allergic Conjunctivitis at American Academy of Ophthalmology 2019 Annual Meeting
September 26, 2019
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it will host an ePoster presentation and discussion of the company’s ALLEVIATE Phase 3 clinical trial of reproxalap in patients...
From
Business Wire News Releases
Aldeyra Therapeutics to Present at 2019 Cantor Global Healthcare Conference
September 25, 2019
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated...
From
Business Wire News Releases
Aldeyra Therapeutics Receives Fast Track Designation for ADX-2191 for the Prevention of Proliferative Vitreoretinopathy
September 24, 2019
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ADX-2191 for the prevention of proliferative...
From
Business Wire News Releases
Aldeyra Therapeutics to Participate in Upcoming Investor Conferences
August 28, 2019
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated...
From
Business Wire News Releases
Aldeyra Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update
August 08, 2019
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated...
From
Business Wire News Releases
Aileron Therapeutics Reports Second Quarter 2019 Financial Results
August 06, 2019
From
GlobeNewswire News Releases
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2019 Financial Results and Corporate Update
August 01, 2019
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated...
From
Business Wire News Releases
Aldeyra Therapeutics Announces Results from the SOLACE Trial in Noninfectious Anterior Uveitis
June 25, 2019
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated...
From
Business Wire News Releases
Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the SOLACE Trial in Noninfectious Anterior Uveitis
June 24, 2019
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated...
From
Business Wire News Releases
Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach
June 24, 2019
Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that William (“Bill”) T. McKee and...
From
GlobeNewswire News Releases
Aldeyra Therapeutics to Participate in the Jefferies 2019 Global Healthcare Conference
May 30, 2019
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated...
From
PR Newswire
Aldeyra Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 09, 2019
- Reported Positive Results from Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis
From
PR Newswire
Aldeyra Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019
May 02, 2019
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated...
From
PR Newswire
Aldeyra Therapeutics Announces Last Patient Dosed in the SOLACE Phase 3 Clinical Trial
April 30, 2019
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated...
From
PR Newswire
Aldeyra Therapeutics Announces Presentation of Phase 2b Dry Eye Disease Results at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 09, 2019
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated...
From
PR Newswire
Recent Analysis Shows Flowserve, Pinnacle West Capital, Aldeyra Therapeutics, Donnelley Financial Solutions, NIC, and Enphase Energy Market Influences — Renewed Outlook, Key Drivers of Growth
April 03, 2019
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Flowserve Corporation...
From
GlobeNewswire News Releases
Aldeyra Therapeutics Announces First Patient Enrolled in the RENEW Phase 3 Clinical Trial for Dry Eye Disease
April 02, 2019
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated...
From
PR Newswire
Medical Device Industry Revenues Should Outpace Healthcare Field
March 27, 2019
Financialnewsmedia.com News Commentary
From
PR Newswire
Medical Device Industry Revenues Should Outpace Healthcare Field
March 27, 2019
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Thinking about buying stock in Aldeyra Therapeutics, Bed Bath & Beyond Inc., Curis Inc., Cronos Group Inc., or Hunter Maritime Acquisition Corp.?
March 26, 2019
InvestorsObserver issues critical PriceWatch Alerts for ALDX, BBBY, CRIS, CRON, and HUNT.
From
PR Newswire
Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis
March 26, 2019
- Primary endpoint of ocular itch score area under the curve achieved for both tested reproxalap concentrations
From
PR Newswire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis
March 25, 2019
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated...
From
PR Newswire
Stoke Therapeutics Appoints Industry Veteran Stephen Tulipano as Chief Financial Officer
March 19, 2019
Stoke Therapeutics appointed Stephen J. Tulipano, CPA, MBA as chief financial officer.
From
Business Wire News Releases
Aldeyra Therapeutics Announces Year-End 2018 Financial Results
March 07, 2019
- Results from the ALLEVIATE Phase 3 Clinical Trial in Allergic Conjunctivitis Expected in Early 2019
From
PR Newswire
Aldeyra Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Friday, March 8, 2019
March 01, 2019
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated...
From
PR Newswire
Aldeyra Therapeutics Provides Update on Ophthalmic Programs at 2019 Research & Development Day
February 27, 2019
Phase 3 Results from ALLEVIATE Trial in Allergic Conjunctivitis Expected in Early 2019
From
PR Newswire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.